Nanomedicine-based strategies to counter chemoresistance in diffuse large B-cell lymphoma.
Chemoresistance is attributed to the incidence of relapse and treatment failure, despite the new advancements in chemoimmunotherapy for diffuse large B-cell lymphoma (DLBCL). The genesis of resistance is dependent on the complex interrelatedness of tumor-intrinsic factors comprising genetic and epigenetic changes, disr...